Masayuki Tazawa, A. Kitahara, Masanori Tsuchida, Keiichi Honma, Toshiro Niki
{"title":"A Surgical Case of Primary Perivascular Epithelioid Cell Tumor of the Lung","authors":"Masayuki Tazawa, A. Kitahara, Masanori Tsuchida, Keiichi Honma, Toshiro Niki","doi":"10.2482/haigan.63.1000","DOIUrl":"https://doi.org/10.2482/haigan.63.1000","url":null,"abstract":"","PeriodicalId":12820,"journal":{"name":"Haigan","volume":"92 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139171115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
━━ Molecular-targeted drugs for specific genetic aberrations are already used for lung cancer treatment in clinical practice, and new molecular-targeted drugs are also currently in clinical development. Personalized treatment for lung cancer based on genomic medicine, which simultaneously investigates multiple genes of patients with lung cancer and detects genetic aberrations, is performed in Japan. Recently, advances in DNA analysis technologies have enabled the accurate detection of genetic aberrations from a tiny DNA sample, and liquid biopsies using bodily fluids, such as peripheral blood, urine or saliva, are emerging as genomic analysis methods for cancer. Many investigations have suggested that liquid biopsies, particularly those analyzing the cell-free DNA (cfDNA) in peripheral blood samples, may become useful biomarkers for lung cancer therapies. We herein report the recent advances in cfDNA analysis technologies using digital polymerase chain reaction or nextgeneration sequencing and reviewed the recent findings from investigations on the potential clinical application of these technologies to the early diagnosis of lung cancer, selection of anti-lung cancer drugs and prediction of the efficacy of anti-lung cancer drugs. Finally, we discuss future issues and perspectives concerning cfDNA analysis technologies for clinical applications. (JJLC. 2020;60:90-98) KEY WORDS━━ Cell-free DNA, Liquid biopsy, Genomic medicine for lung cancer, Digital PCR, Next generation sequencer Corresponding author: Yasushi Goto. Received December 26, 2019; accepted February 13, 2020. 要旨━━肺癌治療においては,遺伝子異常を標的とした 分子標的治療が既に実臨床で行われ,新たな分子標的治 療薬も開発されている.肺癌患者の多数の遺伝子を同時 に調べ,遺伝子変異を明らかにすることにより,患者個々 の病態に合わせて診療を行う肺癌ゲノム医療が日本でも 実践されている.近年,DNA解析機器の技術革新によ り,微量の DNAから正確に遺伝子変異を検出すること が可能になり,末梢血,尿や唾液などの体液を用いて癌 の診療を行うリキッドバイオプシーが癌ゲノム医療にお いて注目されている.リキッドバイオプシーのなかでも, 患者の末梢血中に存在する cell-free DNA(cfDNA)を解 析する医療技術は,肺癌の診断や予後予測に有用なバイ オマーカーになる可能性が多くの研究で検討されてい る.本総説では,cfDNAおよびデジタル PCRと次世代 シークエンサーによる cfDNA解析技術の進歩について 概説するとともに,この cfDNA解析技術を肺癌の早期 診断,肺癌治療薬の選択,肺癌治療薬の効果予測に応用 しようとする最新の研究結果を解説した.また,cfDNA 解析技術を肺癌治療に応用するうえでの今後の課題と展 望についても言及した. 1国立がん研究センター中央病院呼吸器内科. 論文責任者:後藤 悌. 受付日:2019年 12月 26日,採択日:2020年 2月 13日. (肺癌.2020;60:90-98) 2020 The Japan Lung Cancer Society Clinical Usefulness and Future Issue of Cell-free DNA Analysis Technologies―Goto Japanese Journal of Lung Cancer―Vol 60, No 2, Apr 20, 2020―www.haigan.gr.jp 91 索引用語━━ Cell-free DNA,リキッドバイオプシー,肺 癌ゲノム医療,デジタル PCR,次世代シークエンサー
{"title":"Updated Genomic Medicine for Lung Cancer: The Clinical Usefulness and Future Issues Associated with Analytical Technologies for Cell-free DNA in Peripheral Blood","authors":"Y. Goto","doi":"10.2482/haigan.60.90","DOIUrl":"https://doi.org/10.2482/haigan.60.90","url":null,"abstract":"━━ Molecular-targeted drugs for specific genetic aberrations are already used for lung cancer treatment in clinical practice, and new molecular-targeted drugs are also currently in clinical development. Personalized treatment for lung cancer based on genomic medicine, which simultaneously investigates multiple genes of patients with lung cancer and detects genetic aberrations, is performed in Japan. Recently, advances in DNA analysis technologies have enabled the accurate detection of genetic aberrations from a tiny DNA sample, and liquid biopsies using bodily fluids, such as peripheral blood, urine or saliva, are emerging as genomic analysis methods for cancer. Many investigations have suggested that liquid biopsies, particularly those analyzing the cell-free DNA (cfDNA) in peripheral blood samples, may become useful biomarkers for lung cancer therapies. We herein report the recent advances in cfDNA analysis technologies using digital polymerase chain reaction or nextgeneration sequencing and reviewed the recent findings from investigations on the potential clinical application of these technologies to the early diagnosis of lung cancer, selection of anti-lung cancer drugs and prediction of the efficacy of anti-lung cancer drugs. Finally, we discuss future issues and perspectives concerning cfDNA analysis technologies for clinical applications. (JJLC. 2020;60:90-98) KEY WORDS━━ Cell-free DNA, Liquid biopsy, Genomic medicine for lung cancer, Digital PCR, Next generation sequencer Corresponding author: Yasushi Goto. Received December 26, 2019; accepted February 13, 2020. 要旨━━肺癌治療においては,遺伝子異常を標的とした 分子標的治療が既に実臨床で行われ,新たな分子標的治 療薬も開発されている.肺癌患者の多数の遺伝子を同時 に調べ,遺伝子変異を明らかにすることにより,患者個々 の病態に合わせて診療を行う肺癌ゲノム医療が日本でも 実践されている.近年,DNA解析機器の技術革新によ り,微量の DNAから正確に遺伝子変異を検出すること が可能になり,末梢血,尿や唾液などの体液を用いて癌 の診療を行うリキッドバイオプシーが癌ゲノム医療にお いて注目されている.リキッドバイオプシーのなかでも, 患者の末梢血中に存在する cell-free DNA(cfDNA)を解 析する医療技術は,肺癌の診断や予後予測に有用なバイ オマーカーになる可能性が多くの研究で検討されてい る.本総説では,cfDNAおよびデジタル PCRと次世代 シークエンサーによる cfDNA解析技術の進歩について 概説するとともに,この cfDNA解析技術を肺癌の早期 診断,肺癌治療薬の選択,肺癌治療薬の効果予測に応用 しようとする最新の研究結果を解説した.また,cfDNA 解析技術を肺癌治療に応用するうえでの今後の課題と展 望についても言及した. 1国立がん研究センター中央病院呼吸器内科. 論文責任者:後藤 悌. 受付日:2019年 12月 26日,採択日:2020年 2月 13日. (肺癌.2020;60:90-98) 2020 The Japan Lung Cancer Society Clinical Usefulness and Future Issue of Cell-free DNA Analysis Technologies―Goto Japanese Journal of Lung Cancer―Vol 60, No 2, Apr 20, 2020―www.haigan.gr.jp 91 索引用語━━ Cell-free DNA,リキッドバイオプシー,肺 癌ゲノム医療,デジタル PCR,次世代シークエンサー","PeriodicalId":12820,"journal":{"name":"Haigan","volume":"63 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141210992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
━━ Molecular-targeted drugs for specific genetic aberrations are already used for lung cancer treatment in clinical practice, and new molecular-targeted drugs are also currently in clinical development. Personalized treatment for lung cancer based on genomic medicine, which simultaneously investigates multiple genes of patients with lung cancer and detects genetic aberrations, is performed in Japan. Recently, advances in DNA analysis technologies have enabled the accurate detection of genetic aberrations from a tiny DNA sample, and liquid biopsies using bodily fluids, such as peripheral blood, urine or saliva, are emerging as genomic analysis methods for cancer. Many investigations have suggested that liquid biopsies, particularly those analyzing the cell-free DNA (cfDNA) in peripheral blood samples, may become useful biomarkers for lung cancer therapies. We herein report the recent advances in cfDNA analysis technologies using digital polymerase chain reaction or nextgeneration sequencing and reviewed the recent findings from investigations on the potential clinical application of these technologies to the early diagnosis of lung cancer, selection of anti-lung cancer drugs and prediction of the efficacy of anti-lung cancer drugs. Finally, we discuss future issues and perspectives concerning cfDNA analysis technologies for clinical applications. (JJLC. 2020;60:90-98) KEY WORDS━━ Cell-free DNA, Liquid biopsy, Genomic medicine for lung cancer, Digital PCR, Next generation sequencer Corresponding author: Yasushi Goto. Received December 26, 2019; accepted February 13, 2020. 要旨━━肺癌治療においては,遺伝子異常を標的とした 分子標的治療が既に実臨床で行われ,新たな分子標的治 療薬も開発されている.肺癌患者の多数の遺伝子を同時 に調べ,遺伝子変異を明らかにすることにより,患者個々 の病態に合わせて診療を行う肺癌ゲノム医療が日本でも 実践されている.近年,DNA解析機器の技術革新によ り,微量の DNAから正確に遺伝子変異を検出すること が可能になり,末梢血,尿や唾液などの体液を用いて癌 の診療を行うリキッドバイオプシーが癌ゲノム医療にお いて注目されている.リキッドバイオプシーのなかでも, 患者の末梢血中に存在する cell-free DNA(cfDNA)を解 析する医療技術は,肺癌の診断や予後予測に有用なバイ オマーカーになる可能性が多くの研究で検討されてい る.本総説では,cfDNAおよびデジタル PCRと次世代 シークエンサーによる cfDNA解析技術の進歩について 概説するとともに,この cfDNA解析技術を肺癌の早期 診断,肺癌治療薬の選択,肺癌治療薬の効果予測に応用 しようとする最新の研究結果を解説した.また,cfDNA 解析技術を肺癌治療に応用するうえでの今後の課題と展 望についても言及した. 1国立がん研究センター中央病院呼吸器内科. 論文責任者:後藤 悌. 受付日:2019年 12月 26日,採択日:2020年 2月 13日. (肺癌.2020;60:90-98) 2020 The Japan Lung Cancer Society Clinical Usefulness and Future Issue of Cell-free DNA Analysis Technologies―Goto Japanese Journal of Lung Cancer―Vol 60, No 2, Apr 20, 2020―www.haigan.gr.jp 91 索引用語━━ Cell-free DNA,リキッドバイオプシー,肺 癌ゲノム医療,デジタル PCR,次世代シークエンサー
{"title":"Updated Genomic Medicine for Lung Cancer: The Clinical Usefulness and Future Issues Associated with Analytical Technologies for Cell-free DNA in Peripheral Blood","authors":"Y. Goto","doi":"10.2482/haigan.60.90","DOIUrl":"https://doi.org/10.2482/haigan.60.90","url":null,"abstract":"━━ Molecular-targeted drugs for specific genetic aberrations are already used for lung cancer treatment in clinical practice, and new molecular-targeted drugs are also currently in clinical development. Personalized treatment for lung cancer based on genomic medicine, which simultaneously investigates multiple genes of patients with lung cancer and detects genetic aberrations, is performed in Japan. Recently, advances in DNA analysis technologies have enabled the accurate detection of genetic aberrations from a tiny DNA sample, and liquid biopsies using bodily fluids, such as peripheral blood, urine or saliva, are emerging as genomic analysis methods for cancer. Many investigations have suggested that liquid biopsies, particularly those analyzing the cell-free DNA (cfDNA) in peripheral blood samples, may become useful biomarkers for lung cancer therapies. We herein report the recent advances in cfDNA analysis technologies using digital polymerase chain reaction or nextgeneration sequencing and reviewed the recent findings from investigations on the potential clinical application of these technologies to the early diagnosis of lung cancer, selection of anti-lung cancer drugs and prediction of the efficacy of anti-lung cancer drugs. Finally, we discuss future issues and perspectives concerning cfDNA analysis technologies for clinical applications. (JJLC. 2020;60:90-98) KEY WORDS━━ Cell-free DNA, Liquid biopsy, Genomic medicine for lung cancer, Digital PCR, Next generation sequencer Corresponding author: Yasushi Goto. Received December 26, 2019; accepted February 13, 2020. 要旨━━肺癌治療においては,遺伝子異常を標的とした 分子標的治療が既に実臨床で行われ,新たな分子標的治 療薬も開発されている.肺癌患者の多数の遺伝子を同時 に調べ,遺伝子変異を明らかにすることにより,患者個々 の病態に合わせて診療を行う肺癌ゲノム医療が日本でも 実践されている.近年,DNA解析機器の技術革新によ り,微量の DNAから正確に遺伝子変異を検出すること が可能になり,末梢血,尿や唾液などの体液を用いて癌 の診療を行うリキッドバイオプシーが癌ゲノム医療にお いて注目されている.リキッドバイオプシーのなかでも, 患者の末梢血中に存在する cell-free DNA(cfDNA)を解 析する医療技術は,肺癌の診断や予後予測に有用なバイ オマーカーになる可能性が多くの研究で検討されてい る.本総説では,cfDNAおよびデジタル PCRと次世代 シークエンサーによる cfDNA解析技術の進歩について 概説するとともに,この cfDNA解析技術を肺癌の早期 診断,肺癌治療薬の選択,肺癌治療薬の効果予測に応用 しようとする最新の研究結果を解説した.また,cfDNA 解析技術を肺癌治療に応用するうえでの今後の課題と展 望についても言及した. 1国立がん研究センター中央病院呼吸器内科. 論文責任者:後藤 悌. 受付日:2019年 12月 26日,採択日:2020年 2月 13日. (肺癌.2020;60:90-98) 2020 The Japan Lung Cancer Society Clinical Usefulness and Future Issue of Cell-free DNA Analysis Technologies―Goto Japanese Journal of Lung Cancer―Vol 60, No 2, Apr 20, 2020―www.haigan.gr.jp 91 索引用語━━ Cell-free DNA,リキッドバイオプシー,肺 癌ゲノム医療,デジタル PCR,次世代シークエンサー","PeriodicalId":12820,"journal":{"name":"Haigan","volume":"19 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141211163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：